ERBB2 and ductal breast carcinoma in situ: This ‘negative selection’ phenomenon was observed in patients with clonally related HER2-positive DCIS and HER2-negative ipsilateral invasive recurrence within a genomic analysis by the Grand Challenge PRECISION Consortium [18].